Clinical trial · Observational
Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer
NCT01591772CI-TRIAL-00058824completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn about possible changes in brain anatomy and function, and in thinking abilities, such as memory skills, in patients with ovarian cancer who receive treatment with chemotherapy. Cancer patients treated with chemotherapy may experience changes in thinking abilities, and these may interfere with quality of life. Most of the research to date has involved patients with breast cancer, and there are no studies in women with ovarian cancer looking at at treatment-related changes in brain anatomy and function.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Peritoneal Cancer | Malignant Peritoneal Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neuroimaging & Neuropsychological Evaluation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- diagnosed with ovarian that recieved chemo
- interventionNames
- Other: Neuroimaging & Neuropsychological Evaluation
- label
- healthy controls
- interventionNames
- Other: Neuroimaging & Neuropsychological Evaluation
Primary outcomes (2)
- measure
- alterations in regional brain volume
- timeFrame
- 1 year
- description
- will undergo structural MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Three to five T1 weighted sagittal slices are collected to localize the anterior and posterior commissures. Functional imaging: Blood Oxygenation Level-Dependent (BOLD) contrast imaging, which reflects changes in venous deoxyhemoglobin associated with neuronal activity, will be used.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 21 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * diagnosed with stage I-IV ovarian, peritoneal or fallopian tube cancer * completed first-line taxane and platinum-based chemotherapy 1-4 months prior to being enrolled in the study (can be on bevacizumab maintenance) * in remission of their disease at the time of enrollment between 21 and 70 years of age * fluent in English * in the judgment of the consenting professional, have capacity to give consent Healthy Control Inclusion Criteria: * no diagnosis of cancer except basal cell carcinoma * between 21 and 70 years of age * fluent in English * has a mini-mental state exam (MMSE) score of 26 or higher * in the judgment of the consenting professional, have capacity to give consent Exclusion Criteria: * active or recurrent disease, or diagnosis of another cancer (except basal cell carcinoma) as per medical records at the time of enrollment * exposure to chemotherapy or radiation therapy for any medical condition unrelated to ovarian cancer * on hormonal therapy at the time of enrollment * neurological disorder or moderate to severe head trauma (loss of consciousness \> 60 min) * neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc. * self-reported Axis I psychiatric disorder (DSM-IV), major affective disorder (untreated), bipolar disorder, schizophrenia * unable to complete cognitive tests * with standard contraindications to MRI examinations Healthy Control Exclusion Criteria: * exposure to chemotherapy or radiation therapy for any medical condition * on hormone replacement therapy at the time of enrollment * neurological disorder or moderate to severe head trauma (loss of consciousness \> 60 min) * neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.
References
Publications (0)
Data not yet available
No reference posted for this study.